PhaseWell Research, a Nashville-based multisite clinical research company, has acquired Chase Medical Research, which has sites in Waterbury and Hamden.
PhaseWell Research, a Nashville-based multisite clinical research company, has acquired Chase Medical Research, which has sites in Waterbury and Hamden.
The deal adds to PhaseWell’s growing Northeast footprint and broadens its capabilities in cardiometabolic and central nervous system clinical trials, the company said.
Terms of the deal were not disclosed.
Chase Medical Research has been conducting clinical trials in endocrine and metabolic disease, cardiovascular conditions, CNS disorders, respiratory and vaccine research, pain, gastrointestinal and urologic conditions, as well as women’s and men’s health, for more than 20 years.
PhaseWell said its network has collectively completed more than 2,200 clinical trials and contributed to the approval of more than 185 therapies. The company’s portfolio spans Phase I through Phase IV trials across oncology, CNS, cardiometabolic, dermatology and behavioral health.
Chase Medical Research was founded by Dr. Joseph Soufer, a principal investigator and key opinion leader who will remain with the combined organization.
He said the partnership will allow Chase Medical Research to grow its Connecticut sites while extending its cardiometabolic expertise across PhaseWell’s national network.
“We are creating more opportunities to bring innovative clinical trials to patients in Connecticut while taking Chase Medical’s expertise outside our four walls,” Soufer said.
